VEGF inhibition and renal thrombotic microangiopathy.

The glomerular microvasculature is particularly susceptible to injury in thrombotic microangiopathy, but the mechanisms by which this occurs are unclear. We report the cases of six patients who were treated with bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in whom glomerular disease characteristic of thrombotic microangiopathy developed. To show that local reduction of VEGF within the kidney is sufficient to trigger the pathogenesis of thrombotic microangiopathy, we used conditional gene targeting to delete VEGF from renal podocytes in adult mice; this resulted in a profound thrombotic glomerular injury. These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy.

[1]  N Stephen Pollitt,et al.  Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia , 2007, Hypertension.

[2]  Yuan Zhang,et al.  Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions , 2007, Proceedings of the National Academy of Sciences.

[3]  Gregory Riely,et al.  Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[4]  B. Ballermann.  Contribution of the Endothelium to the Glomerular Permselectivity Barrier in Health and Disease , 2007, Nephron Physiology.

[5]  H. Izzedine,et al.  Thrombotic microangiopathy and anti-VEGF agents. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  B. Rovin,et al.  Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma , 2007, Nature Clinical Practice Nephrology.

[7]  F. Peale,et al.  Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies , 2007, Proceedings of the National Academy of Sciences.

[8]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  R. Toto,et al.  Nephrotic syndrome after bevacizumab: case report and literature review. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  B. Ballermann.  Glomerular endothelial cell differentiation. , 2005, Kidney international.

[11]  K. Lim,et al.  Urinary placental growth factor and risk of preeclampsia. , 2005, JAMA.

[12]  K. Lim,et al.  Circulating angiogenic factors and the risk of preeclampsia. , 2004, The New England journal of medicine.

[13]  D. Gillatt,et al.  Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. , 2003, American journal of physiology. Renal physiology.

[14]  R. Kalluri,et al.  Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria* , 2003, The Journal of Biological Chemistry.

[15]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[16]  Y. G. Kim,et al.  Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. , 2001, Kidney international.

[17]  A. Blom,et al.  Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. , 2001, American journal of physiology. Renal physiology.

[18]  N. Janjić,et al.  VEGF(165) mediates glomerular endothelial repair. , 1999, The Journal of clinical investigation.